CD38

CD38 inhibitor 1 is a potent CD38 inhibitor that is effective against human CD38 (IC50 value is 7.3 nM) and mouse CD38 (IC50 value is 1.9 nM).

Isatuximab is a monoclonal antibody targeting the transmembrane receptor and extracellular enzyme CD38 in malignant cells of the hematological system, a highly expressed protein in multiple myeloma. It exhibits antitumor activity, antibody-dependent cytotoxicity, complement-dependent cytotoxicity, and antibody-dependent cytophagocytosis, directly inducing apoptosis without crosslinking. Isatuximab inhibits CD38 extracellular enzyme activity, affecting various cellular functions.

Luteolinidin chloride is a natural product. It is a potent CD38 inhibitor which can protect the heart against I/R injury with preservation of eNOS function and prevention of endothelial dysfunction in vivo.

Felzartamab(MOR-202) is a human-targeted monoclonal antibody to CD38 for the study of multiple myeloma and advanced antibody-mediated rejection of allogeneic kidney transplants.

Mezagitamab (TAK-079) is a fully humanized IgG1λ monoclonal antibody against CD38 with high affinity for CD38-expressing cells (including plasma mother cells, plasma cells, and natural killer cells), which depletes CD38-expressing tumor cells through antibody- and complement-dependent cytotoxicity Mezagitamab may be used in the study of recurrent/refractory multiple myeloma (RRMM), which is the most common form of cancer. multiple myeloma (RRMM) and primary thrombocytopenic purpura (ITP).

RBN013209 is a potent CD38 inhibitor. RBN013209 is useful in the treatment of cancer.

MK-0159 is an orally available, highly potent CD38 inhibitor with myocardial injury protection for the study of cardiac ischemia and reperfusion injury.

SAR442257 is a humanized IgG4-S228P (κ type) monoclonal antibody designed to target CD38 on the surface of multiple myeloma cells, while also co-stimulating CD3 and CD28 molecules on T cells.

Erzotabart, an IgG1-kappa monoclonal antibody targeting CD38 (ADP-ribosyl cyclase 1, cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, cADPR1) in Homo sapiens, exhibits antineoplastic activity [1].

6-Alkyne-F-araNAD is an irreversible CD38 inhibitor that aids in better visualization of intracellular CD38 localization when used alongside other fluorescent probes (such as SR101−F-araNMN).

AMG-424 (XmAb968) is a human bispecific antibody (bsAb) targeting CD38 and CD3E. It effectively kills cancer cells that express CD38, stimulates T cell proliferation, and reduces cytokine release. AMG-424 exhibits antitumor activity in mouse cancer models with bone marrow invasion and induces peripheral B cell depletion in cynomolgus monkeys. It is used in studies of multiple myeloma. Recommended isotype control: half-IG G1-kappa/(scFv-heavy-lambda)-h-CH2-CH3.

CD38 Inhibitor 3 (compound 1), with an IC50 of 11 nM, is a potent agent that enhances mitochondrial biogenesis, diminishes lactate levels, and augments both NAD+ content and Nrf2 expression. In a Pus1 - - mouse model of mitochondrial myopathy, it also elevates muscle function and bolstering exercise capacity [1].